GU Cancers 2024 | Treating patients with bladder cancer who won’t undergo radical cystectomy

Joseph Jacob, MD, MSc, Upstate Medical University, Syracuse, NY, comments on treatment options for patients with bladder cancer who can’t or won’t undergo radical cystectomy. Salvage therapies consisting of intravesical or systemic therapy such as pembrolizumab are currently investigation. Other intravesical therapies such as RNA viral vectors and the recently approved nadofaragene firadenovec are additionally highlighted. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.